BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marthey L, Mateus C, Mussini C, Nachury M, Nancey S, Grange F, Zallot C, Peyrin-Biroulet L, Rahier JF, Bourdier de Beauregard M, Mortier L, Coutzac C, Soularue E, Lanoy E, Kapel N, Planchard D, Chaput N, Robert C, Carbonnel F. Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease. J Crohns Colitis. 2016;10:395-401. [PMID: 26783344 DOI: 10.1093/ecco-jcc/jjv227] [Cited by in Crossref: 148] [Cited by in F6Publishing: 132] [Article Influence: 29.6] [Reference Citation Analysis]
Number Citing Articles
1 Yamauchi Y, Arai M, Akizue N, Ohta Y, Okimoto K, Matsumura T, Fan MM, Imai C, Tawada A, Kato J, Kato N, Takiguchi Y. Colonoscopic evaluation of diarrhea/colitis occurring as an immune-related adverse event. Jpn J Clin Oncol 2021;51:363-70. [PMID: 33290513 DOI: 10.1093/jjco/hyaa203] [Reference Citation Analysis]
2 Ibraheim H, Perucha E, Powell N. Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors. Rheumatology (Oxford) 2019;58:vii17-28. [PMID: 31816081 DOI: 10.1093/rheumatology/kez465] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 14.0] [Reference Citation Analysis]
3 Abousaway O, Rakhshandehroo T, Van den Abbeele AD, Kircher MF, Rashidian M. Noninvasive Imaging of Cancer Immunotherapy. Nanotheranostics 2021;5:90-112. [PMID: 33391977 DOI: 10.7150/ntno.50860] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
4 Bertha M, Bellaguara E, Kuzel T, Hanauer S. Checkpoint Inhibitor-Induced Colitis: A New Type of Inflammatory Bowel Disease? ACG Case Rep J. 2017;4:e112. [PMID: 29043290 DOI: 10.14309/crj.2017.112] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
5 Dougan M. Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives. Curr Gastroenterol Rep 2020;22. [DOI: 10.1007/s11894-020-0752-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
6 Favara DM, Spain L, Au L, Clark J, Daniels E, Diem S, Chauhan D, Turajlic S, Powell N, Larkin JM, Yousaf N. Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma. ESMO Open. 2020;5. [PMID: 32641348 DOI: 10.1136/esmoopen-2019-000585] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
7 Bellaguarda E, Hanauer S. Checkpoint Inhibitor-Induced Colitis. Am J Gastroenterol. 2020;115:202-210. [PMID: 31922959 DOI: 10.14309/ajg.0000000000000497] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
8 Shivaji UN, Jeffery L, Gui X, Smith SCL, Ahmad OF, Akbar A, Ghosh S, Iacucci M. Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. Therap Adv Gastroenterol 2019;12:1756284819884196. [PMID: 31723355 DOI: 10.1177/1756284819884196] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 13.0] [Reference Citation Analysis]
9 Wojtukiewicz MZ, Rek MM, Karpowicz K, Górska M, Polityńska B, Wojtukiewicz AM, Moniuszko M, Radziwon P, Tucker SC, Honn KV. Inhibitors of immune checkpoints-PD-1, PD-L1, CTLA-4-new opportunities for cancer patients and a new challenge for internists and general practitioners. Cancer Metastasis Rev 2021. [PMID: 34236546 DOI: 10.1007/s10555-021-09976-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Tang T, Abu-Sbeih H, Luo W, Lum P, Qiao W, Bresalier RS, Richards DM, Wang Y. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scand J Gastroenterol. 2019;54:538-545. [PMID: 31079556 DOI: 10.1080/00365521.2019.1594356] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 7.5] [Reference Citation Analysis]
11 Chhabra N, Kennedy J. A Review of Cancer Immunotherapy Toxicity: Immune Checkpoint Inhibitors. J Med Toxicol 2021. [PMID: 33826117 DOI: 10.1007/s13181-021-00833-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
12 Baroudjian B, Arangalage D, Cuzzubbo S, Hervier B, Lebbé C, Lorillon G, Tazi A, Zalcman G, Bouattour M, Lioté F, Gautier JF, Brosseau S, Lourenco N, Delyon J; PATIO group. Management of immune-related adverse events resulting from immune checkpoint blockade. Expert Rev Anticancer Ther 2019;19:209-22. [PMID: 30572735 DOI: 10.1080/14737140.2019.1562342] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
13 Mekki A, Dercle L, Lichtenstein P, Marabelle A, Michot JM, Lambotte O, Le Pavec J, De Martin E, Balleyguier C, Champiat S, Ammari S. Detection of immune-related adverse events by medical imaging in patients treated with anti-programmed cell death 1. Eur J Cancer 2018;96:91-104. [PMID: 29698933 DOI: 10.1016/j.ejca.2018.03.006] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 19.7] [Reference Citation Analysis]
14 Portenkirchner C, Kienle P, Horisberger K. Checkpoint Inhibitor-Induced Colitis-A Clinical Overview of Incidence, Prognostic Implications and Extension of Current Treatment Options. Pharmaceuticals (Basel) 2021;14:367. [PMID: 33923423 DOI: 10.3390/ph14040367] [Reference Citation Analysis]
15 Brahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, Gerber DE, Hamad L, Hansen E, Johnson DB, Lacouture ME, Masters GA, Naidoo J, Nanni M, Perales MA, Puzanov I, Santomasso BD, Shanbhag SP, Sharma R, Skondra D, Sosman JA, Turner M, Ernstoff MS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer 2021;9:e002435. [PMID: 34172516 DOI: 10.1136/jitc-2021-002435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
16 Anfossi S, Calin GA. Gut microbiota: a new player in regulating immune- and chemo-therapy efficacy. Cancer Drug Resist 2020;3:356-70. [PMID: 33062956 DOI: 10.20517/cdr.2020.04] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
17 Fernandes DC, Jervoise N Andreyev H. Chronic diarrhoea in an oncology patient - Clinical assessment and decision making. Best Pract Res Clin Gastroenterol 2020;48-49:101708. [PMID: 33317791 DOI: 10.1016/j.bpg.2020.101708] [Reference Citation Analysis]
18 Pickwell-smith BA, So AC, Board RE. Managing side effects of cancer immunotherapy for the acute physician. Br J Hosp Med 2018;79:372-7. [DOI: 10.12968/hmed.2018.79.7.372] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Tarhini AA, Joshi I, Garner F. Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma. Immunotherapy 2021;13:1011-29. [PMID: 34157863 DOI: 10.2217/imt-2021-0119] [Reference Citation Analysis]
20 Mohamed AA, Richards CJ, Boyle K, Faust G. Severe inflammatory ileitis resulting in ileal perforation in association with combination immune checkpoint blockade for metastatic malignant melanoma. BMJ Case Rep 2018;2018:bcr-2018-224913. [PMID: 29622719 DOI: 10.1136/bcr-2018-224913] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
21 Cramer P, Bresalier RS. Gastrointestinal and Hepatic Complications of Immune Checkpoint Inhibitors. Curr Gastroenterol Rep 2017;19:3. [PMID: 28124291 DOI: 10.1007/s11894-017-0540-6] [Cited by in Crossref: 81] [Cited by in F6Publishing: 63] [Article Influence: 20.3] [Reference Citation Analysis]
22 Hu Y, Gong J, Zhang L, Li X, Zhao B, Hai X. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system. Int Immunopharmacol. 2020;84:106601. [PMID: 32422528 DOI: 10.1016/j.intimp.2020.106601] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
23 Dougan M. Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. Front Immunol 2017;8:1547. [PMID: 29230210 DOI: 10.3389/fimmu.2017.01547] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 16.8] [Reference Citation Analysis]
24 Kichloo A, Albosta M, Dahiya D, Guidi JC, Aljadah M, Singh J, Shaka H, Wani F, Kumar A, Lekkala M. Systemic adverse effects and toxicities associated with immunotherapy: A review. World J Clin Oncol 2021; 12(3): 150-163 [PMID: 33767971 DOI: 10.5306/wjco.v12.i3.150] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Duval L, Habes S, Chatellier T, Guerzider P, Bossard C, Masliah C, Archambeaud I, Touchefeu Y, Matysiak-Budnik T. Nivolumab-induced celiac-like enteropathy in patient with metastatic renal cell carcinoma: Case report and review of the literature. Clin Case Rep 2019;7:1689-93. [PMID: 31534728 DOI: 10.1002/ccr3.2342] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
26 Puzanov I, Diab A, Abdallah K, Bingham CO, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J Immunother Cancer. 2017;5:95. [PMID: 29162153 DOI: 10.1186/s40425-017-0300-z] [Cited by in Crossref: 753] [Cited by in F6Publishing: 671] [Article Influence: 188.3] [Reference Citation Analysis]
27 Tan B, Li Y, Xu Y, Chen M, Wang M, Qian J. Recognition and management of the gastrointestinal and hepatic immune-related adverse events. Asia Pac J Clin Oncol 2020;16:95-102. [PMID: 32077625 DOI: 10.1111/ajco.13317] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Alcantar D, Al-Jaashaami L, Giron F. A Case of Immune Checkpoint Inhibitor Refractory Colitis Treated with Mycophenolate and High-dose Steroids. Cureus 2019;11:e6392. [PMID: 31938669 DOI: 10.7759/cureus.6392] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
29 Kim H, Ha SY, Kim J, Kang M, Lee J. Severe cytomegalovirus gastritis after pembrolizumab in a patient with melanoma. Curr Oncol 2020;27:e436-9. [PMID: 32905211 DOI: 10.3747/co.27.6163] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
30 Dougan M, Wang Y, Rubio-Tapia A, Lim JK. AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. Gastroenterology. 2021;160:1384-1393. [PMID: 33080231 DOI: 10.1053/j.gastro.2020.08.063] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
31 Som A, Mandaliya R, Alsaadi D, Farshidpour M, Charabaty A, Malhotra N, Mattar MC. Immune checkpoint inhibitor-induced colitis: A comprehensive review. World J Clin Cases 2019; 7(4): 405-418 [PMID: 30842952 DOI: 10.12998/wjcc.v7.i4.405] [Cited by in CrossRef: 78] [Cited by in F6Publishing: 59] [Article Influence: 39.0] [Reference Citation Analysis]
32 Grover S, Srivastava A. Lymphocytic colitis-like pattern of mucosal injury and the challenges in diagnosing cancer immunotherapy-related toxicity. Cancer 2019;125:1768-70. [PMID: 30892689 DOI: 10.1002/cncr.32005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
33 Chaput N, Lepage P, Coutzac C, Soularue E, Le Roux K, Monot C, Boselli L, Routier E, Cassard L, Collins M, Vaysse T, Marthey L, Eggermont A, Asvatourian V, Lanoy E, Mateus C, Robert C, Carbonnel F. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28:1368-1379. [PMID: 28368458 DOI: 10.1093/annonc/mdx108] [Cited by in Crossref: 416] [Cited by in F6Publishing: 382] [Article Influence: 138.7] [Reference Citation Analysis]
34 Iranzo I, Huguet JM, Suárez P, Ferrer-Barceló L, Iranzo V, Sempere J. Endoscopic evaluation of immunotherapy-induced gastrointestinal toxicity. World J Gastrointest Endosc 2018; 10(12): 392-399 [PMID: 30631403 DOI: 10.4253/wjge.v10.i12.392] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
35 Pavlick A, Weber J. Managing Checkpoint Inhibitor Symptoms and Toxicity for Metastatic Melanoma. In: Balch CM, Atkins MB, Garbe C, Gershenwald JE, Halpern AC, Kirkwood JM, Mcarthur GA, Thompson JF, Sober AJ, editors. Cutaneous Melanoma. Cham: Springer International Publishing; 2020. pp. 1187-214. [DOI: 10.1007/978-3-030-05070-2_60] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Soularue E, Lepage P, Colombel JF, Coutzac C, Faleck D, Marthey L, Collins M, Chaput N, Robert C, Carbonnel F. Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut 2018;67:2056-67. [DOI: 10.1136/gutjnl-2018-316948] [Cited by in Crossref: 74] [Cited by in F6Publishing: 62] [Article Influence: 24.7] [Reference Citation Analysis]
37 Bateman AC. Molecules in cancer immunotherapy: benefits and side effects. J Clin Pathol 2018;72:20-4. [DOI: 10.1136/jclinpath-2018-205370] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
38 Hosseini A, Gharibi T, Marofi F, Babaloo Z, Baradaran B. CTLA-4: From mechanism to autoimmune therapy. Int Immunopharmacol 2020;80:106221. [PMID: 32007707 DOI: 10.1016/j.intimp.2020.106221] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 22.0] [Reference Citation Analysis]
39 Gecse KB, Vermeire S. Differential diagnosis of inflammatory bowel disease: imitations and complications. Lancet Gastroenterol Hepatol 2018;3:644-53. [PMID: 30102183 DOI: 10.1016/S2468-1253(18)30159-6] [Cited by in Crossref: 34] [Cited by in F6Publishing: 16] [Article Influence: 11.3] [Reference Citation Analysis]
40 Dougan M, Luoma AM, Dougan SK, Wucherpfennig KW. Understanding and treating the inflammatory adverse events of cancer immunotherapy. Cell 2021;184:1575-88. [PMID: 33675691 DOI: 10.1016/j.cell.2021.02.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
41 Tyan K, Baginska J, Brainard M, Giobbie-hurder A, Severgnini M, Manos M, Haq R, Buchbinder EI, Ott PA, Hodi FS, Rahma OE. Cytokine changes during immune-related adverse events and corticosteroid treatment in melanoma patients receiving immune checkpoint inhibitors. Cancer Immunol Immunother 2021;70:2209-21. [DOI: 10.1007/s00262-021-02855-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
42 Weingarden AR, Rubin SJS, Gubatan J. Immune checkpoint inhibitor-mediated colitis in gastrointestinal malignancies and inflammatory bowel disease. World J Gastrointest Oncol 2021; 13(8): 772-798 [PMID: 34457186 DOI: 10.4251/wjgo.v13.i8.772] [Reference Citation Analysis]
43 Li Y, Wang H, Guo X, Zhou J, Duan L, Si X, Zhang L, Liu X, Qian J, Zhang L. [Clinical Diagnosis and Treatment of Immune-related Adverse Events in Digestive System Related to Immune Checkpoint Inhibitors]. Zhongguo Fei Ai Za Zhi 2019;22:661-5. [PMID: 31650950 DOI: 10.3779/j.issn.1009-3419.2019.10.10] [Reference Citation Analysis]
44 Rocha M, Correia de Sousa J, Salgado M, Araújo A, Pedroto I. Management of Gastrointestinal Toxicity from Immune Checkpoint Inhibitor. GE Port J Gastroenterol 2019;26:268-74. [PMID: 31328141 DOI: 10.1159/000494569] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
45 de Malet A, Antoni G, Collins M, Soularue E, Marthey L, Vaysse T, Coutzac C, Chaput N, Mateus C, Robert C, Carbonnel F. Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. Eur J Cancer 2019;106:106-14. [PMID: 30476730 DOI: 10.1016/j.ejca.2018.10.006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
46 Cheung VTF, Brain O. Immunotherapy induced enterocolitis and gastritis - What to do and when? Best Pract Res Clin Gastroenterol 2020;48-49:101703. [PMID: 33317787 DOI: 10.1016/j.bpg.2020.101703] [Reference Citation Analysis]
47 Li Y, Kang X, Wang H, Guo X, Zhou J, Duan L, Si X, Zhang L, Liu X, Qian J, Zhang L. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system. Thorac Cancer 2020;11:829-34. [PMID: 32107847 DOI: 10.1111/1759-7714.13338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Boussios S, Sheriff M, Rassy E, Moschetta M, Samartzis EP, Hallit R, Sadauskaite A, Katsanos KH, Christodoulou DK, Pavlidis N. Immuno-oncology: a narrative review of gastrointestinal and hepatic toxicities. Ann Transl Med 2021;9:423. [PMID: 33842644 DOI: 10.21037/atm-20-7361] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Kuo JR, Davis AD, Rodriguez EA, Vela MF, Heigh RI, Salomao MA, Gurudu SR. Severe Diarrhea in the Setting of Immune Checkpoint Inhibitors. Case Rep Gastroenterol 2018;12:704-8. [PMID: 30631256 DOI: 10.1159/000493183] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
50 Sun L, Arbesman J, Piliang M. Vitamin D, autoimmunity and immune-related adverse events of immune checkpoint inhibitors. Arch Dermatol Res 2021;313:1-10. [PMID: 32519001 DOI: 10.1007/s00403-020-02094-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
51 Delasos L, Desai A, Lopetegui Lia N, Kethireddy N, Ray C. A Case of Immunotherapy-Induced Colitis Complicated by Perforation and Treated with Infliximab Postoperatively. Case Rep Oncol Med 2019;2019:9069354. [PMID: 31428491 DOI: 10.1155/2019/9069354] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
52 Yamauchi R, Araki T, Mitsuyama K, Tokito T, Ishii H, Yoshioka S, Kuwaki K, Mori A, Yoshimura T, Tsuruta O, Torimura T. The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review. BMC Gastroenterol. 2018;18:135. [PMID: 30170560 DOI: 10.1186/s12876-018-0864-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
53 Cybulska-Stopa B, Gruchała A, Niemiec M. Immune-Related Pancytopenia Induced by Anti-PD-1 Therapy - Interrupt or Continue Treatment - The Role of Immunohistochemical Examination. Case Rep Oncol 2019;12:820-8. [PMID: 31762755 DOI: 10.1159/000504130] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Wang ZH, Shen L. Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors. Chronic Dis Transl Med. 2018;4:1-7. [PMID: 29756118 DOI: 10.1016/j.cdtm.2017.12.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Palmieri DJ, Carlino MS. Immune Checkpoint Inhibitor Toxicity. Curr Oncol Rep 2018;20. [DOI: 10.1007/s11912-018-0718-6] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 13.7] [Reference Citation Analysis]
56 Hoefsmit EP, Rozeman EA, Haanen JBAG, Blank CU. Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events. ESMO Open 2019;4:e000472. [PMID: 31423333 DOI: 10.1136/esmoopen-2018-000472] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
57 Abu-Sbeih H, Ali FS, Wang Y. Immune-checkpoint inhibitors induced diarrhea and colitis: a review of incidence, pathogenesis and management. Curr Opin Gastroenterol 2020;36:25-32. [PMID: 31609734 DOI: 10.1097/MOG.0000000000000593] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
58 Akel R, Anouti B, Tfayli A. Late-Onset Inflammatory Bowel Disease-Like Syndrome after Ipilimumab Therapy: A Case Report. Case Rep Oncol. 2017;10:456-461. [PMID: 28626406 DOI: 10.1159/000475709] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
59 Randhawa M, Gaughran G, Archer C, Pavli P, Morey A, Ali S, Yip D. Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report. World J Clin Oncol 2019; 10(10): 350-357 [PMID: 31799150 DOI: 10.5306/wjco.v10.i10.350] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
60 Joosse ME, Nederlof I, Walker LSK, Samsom JN. Tipping the balance: inhibitory checkpoints in intestinal homeostasis. Mucosal Immunol 2019;12:21-35. [PMID: 30498201 DOI: 10.1038/s41385-018-0113-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
61 Nishida T, Iijima H, Adachi S. Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings. World J Gastrointest Pathophysiol 2019; 10(2): 17-28 [PMID: 31559106 DOI: 10.4291/wjgp.v10.i2.17] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
62 Zyla E, Musielak B, Holak TA, Dubin G. Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis. Molecules 2021;26:4848. [PMID: 34443436 DOI: 10.3390/molecules26164848] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Basile D, Di Nardo P, Corvaja C, Garattini SK, Pelizzari G, Lisanti C, Bortot L, Da Ros L, Bartoletti M, Borghi M, Gerratana L, Lombardi D, Puglisi F. Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside. Cancers (Basel) 2019;11:E857. [PMID: 31226812 DOI: 10.3390/cancers11060857] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 14.5] [Reference Citation Analysis]
64 Menon T, Afzali A. Immune-Mediated Colitis. Curr Treat Options Gastroenterol 2019;17:506-23. [PMID: 31741212 DOI: 10.1007/s11938-019-00263-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
65 Yushak M, Chapman P, Robert C, Kudchadkar R. Systemic Therapy Options for Patients With Unresectable Melanoma. American Society of Clinical Oncology Educational Book 2017. [DOI: 10.1200/edbk_174934] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
66 Powell N, Ibraheim H, Raine T, Speight RA, Papa S, Brain O, Green M, Samaan MA, Spain L, Yousaf N, Hunter N, Eldridge L, Pavlidis P, Irving P, Hayee B, Turajlic S, Larkin J, Lindsay JO, Gore M. British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. Lancet Gastroenterol Hepatol 2020;5:679-97. [PMID: 32553146 DOI: 10.1016/S2468-1253(20)30014-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
67 Dougan M, Blidner AG, Choi J, Cooksley T, Glezerman I, Ginex P, Girotra M, Gupta D, Johnson D, Shannon VR, Suarez-Almazor M, Anderson R, Rapoport BL. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors. Support Care Cancer 2020;28:6129-43. [PMID: 32856210 DOI: 10.1007/s00520-020-05707-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
68 Ladak K, Bass AR. Checkpoint inhibitor-associated autoimmunity. Best Pract Res Clin Rheumatol 2018;32:781-802. [PMID: 31427055 DOI: 10.1016/j.berh.2019.03.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
69 Hayashi Y, Hosoe N, Takabayashi K, Limpias Kamiya KJL, Tsugaru K, Shimozaki K, Hirata K, Fukuhara K, Fukuhara S, Mutaguchi M, Sujino T, Sukawa Y, Hamamoto Y, Naganuma M, Takaishi H, Shimoda M, Ogata H, Kanai T. Clinical, Endoscopic, and Pathological Characteristics of Immune Checkpoint Inhibitor-Induced Gastroenterocolitis. Dig Dis Sci. 2021;66:2129-2134. [PMID: 32621258 DOI: 10.1007/s10620-020-06441-w] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
70 Ma C, MacDonald JK, Nguyen TM, Vande Casteele N, Linggi B, Lefevre P, Wang Y, Feagan BG, Jairath V. Pharmacological Interventions for the Prevention and Treatment of Immune Checkpoint Inhibitor-Associated Enterocolitis: A Systematic Review. Dig Dis Sci 2021. [PMID: 33770330 DOI: 10.1007/s10620-021-06948-w] [Reference Citation Analysis]
71 Majem M, García-Martínez E, Martinez M, Muñoz-Couselo E, Rodriguez-Abreu D, Alvarez R, Arance A, Berrocal A, de la Cruz-Merino L, Lopez-Martin JA. SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). Clin Transl Oncol 2020;22:213-22. [PMID: 31993963 DOI: 10.1007/s12094-019-02273-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
72 Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA;  National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36:1714-1768. [PMID: 29442540 DOI: 10.1200/jco.2017.77.6385] [Cited by in Crossref: 1268] [Cited by in F6Publishing: 619] [Article Influence: 422.7] [Reference Citation Analysis]
73 Horisberger K, Portenkirchner C, Rickenbacher A, Biedermann L, Gubler C, Turina M. Complete Recovery of Immune Checkpoint Inhibitor–induced Colitis by Diverting Loop Ileostomy. Journal of Immunotherapy 2020;43:145-8. [DOI: 10.1097/cji.0000000000000309] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
74 Hughes MS, Molina GE, Chen ST, Zheng H, Deshpande V, Fadden R, Sullivan RJ, Dougan M. Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. J Immunother Cancer 2019;7:292. [PMID: 31699151 DOI: 10.1186/s40425-019-0756-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
75 Sakellariou S, Zouki DN, Ziogas DC, Pouloudi D, Gogas H, Delladetsima I. Granulomatous colitis in a patient with metastatic melanoma under immunotherapy: a case report and literature review. BMC Gastroenterol 2021;21:227. [PMID: 34011268 DOI: 10.1186/s12876-021-01812-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Rudzki JD. Management of adverse events related to checkpoint inhibition therapy. Memo 2018;11:132-7. [PMID: 29983828 DOI: 10.1007/s12254-018-0416-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
77 Sebastian S, Neilaj S. Practical guidance for the management of inflammatory bowel disease in patients with cancer. Which treatment? Therap Adv Gastroenterol 2019;12:1756284818817293. [PMID: 30643542 DOI: 10.1177/1756284818817293] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
78 Dahiya DS, Wani F, Guidi JC, Kichloo A. Gastrointestinal Adverse Effects of Immunotherapeutic Agents: A Systematic Review. Gastroenterology Res 2020;13:227-32. [PMID: 33447301 DOI: 10.14740/gr1340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Larkin P, Cherny N, La Carpia D, Guglielmo M, Ostgathe C, Scotté F, Ripamonti C. Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. Annals of Oncology 2018;29:iv111-25. [DOI: 10.1093/annonc/mdy148] [Cited by in Crossref: 43] [Cited by in F6Publishing: 28] [Article Influence: 14.3] [Reference Citation Analysis]
80 O'Reilly M, Mellotte G, Ryan B, O'Connor A. Gastrointestinal side effects of cancer treatments. Ther Adv Chronic Dis 2020;11:2040622320970354. [PMID: 33294145 DOI: 10.1177/2040622320970354] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
81 Zengin ZB, Salgia NJ, Chehrazi-Raffle A, Meza L, Malhotra J, Pal SK. Immune Related Adverse Events: Classification and Management Approaches in Advanced Kidney Cancer. Cancer J 2020;26:432-40. [PMID: 32947311 DOI: 10.1097/PPO.0000000000000473] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
82 Navarini AA, Hruz P, Berger CT, Hou TZ, Schwab C, Gabrysch A, Higgins R, Frede N, Padberg Sgier BC, Kämpe O, Burgener AV, Marquardsen F, Baldin F, Bigler M, Kistner A, Jauch A, Bignucolo O, Meyer B, Meienberg F, Mehling M, Jeker LT, Heijnen I, Daikeler TD, Gebbers JO, Grimbacher B, Sansom DM, Jeker R, Hess C, Recher M. Vedolizumab as a successful treatment of CTLA-4-associated autoimmune enterocolitis. J Allergy Clin Immunol 2017;139:1043-1046.e5. [PMID: 27908448 DOI: 10.1016/j.jaci.2016.08.042] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
83 Johncilla M, Grover S, Zhang X, Jain D, Srivastava A. Morphological spectrum of immune check-point inhibitor therapy-associated gastritis. Histopathology. 2020;76:531-539. [PMID: 31692018 DOI: 10.1111/his.14029] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 23.0] [Reference Citation Analysis]
84 Zhou W, Huang Y, Lai J, Lu J, Feely M, Liu X. Anti-Inflammatory Biologics and Anti-Tumoral Immune Therapies-Associated Colitis: A Focused Review of Literature. Gastroenterology Res 2018;11:174-88. [PMID: 29915627 DOI: 10.14740/gr1041w] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
85 Collins M, Soularue E, Marthey L, Carbonnel F. Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review. Clin Gastroenterol Hepatol. 2020;18:1393-1403.e1. [PMID: 32007539 DOI: 10.1016/j.cgh.2020.01.033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
86 Inthagard J, Edwards J, Roseweir AK. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers. Clin Sci (Lond) 2019;133:181-93. [PMID: 30659159 DOI: 10.1042/CS20181003] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 9.5] [Reference Citation Analysis]
87 Otegbeye EE, Mitchem JB, Park H, Chaudhuri AA, Kim H, Mutch MG, Ciorba MA. Immunity, immunotherapy, and rectal cancer: A clinical and translational science review. Transl Res 2021;231:124-38. [PMID: 33307273 DOI: 10.1016/j.trsl.2020.12.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
88 Sisman G, Barbur E, Saka D, Erdamar Cetin S. Pembrolizumab-induced immune-mediated fatal colitis with concurrent giardia infection. Cancer Immunol Immunother 2021;70:2385-8. [PMID: 33481043 DOI: 10.1007/s00262-020-02815-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
89 Coutzac C, Adam J, Soularue E, Collins M, Racine A, Mussini C, Boselli L, Kamsukom N, Mateus C, Charrier M, Cassard L, Planchard D, Ribrag V, Fizazi K, Loriot Y, Lepage P, Scoazec JY, Robert C, Carbonnel F, Chaput N. Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities. J Crohns Colitis. 2017;11:1238-1246. [PMID: 28967957 DOI: 10.1093/ecco-jcc/jjx081] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 23.0] [Reference Citation Analysis]
90 Furuta Y, Miyamoto H, Naoe H, Shimoda M, Hinokuma Y, Miyamura T, Miyashita A, Fukushima S, Tanaka M, Sasaki Y. Cytomegalovirus Enterocolitis in a Patient with Refractory Immune-Related Colitis. Case Rep Gastroenterol 2020;14:103-9. [PMID: 32231510 DOI: 10.1159/000506186] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
91 Grover S, Dougan M, Tyan K, Giobbie-Hurder A, Blum SM, Ishizuka J, Qazi T, Elias R, Vora KB, Ruan AB, Martin-Doyle W, Manos M, Eastman L, Davis M, Gargano M, Haq R, Buchbinder EI, Sullivan RJ, Ott PA, Hodi FS, Rahma OE. Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor-induced colitis. Cancer. 2020;126:3758-3767. [PMID: 32567084 DOI: 10.1002/cncr.32966] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
92 Pulito C, Cristaudo A, Porta C, Zapperi S, Blandino G, Morrone A, Strano S. Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res 2020;39:210. [PMID: 33028357 DOI: 10.1186/s13046-020-01715-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
93 Arora K, Zhang ML, Goiburú-chenu MB, England J. Pathology of immune checkpoint inhibitor-induced injury of the gastrointestinal tract and hepatobiliary system. Diagnostic Histopathology 2021;27:62-8. [DOI: 10.1016/j.mpdhp.2020.11.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
94 Badgeley A, Anwar H, Modi K, Murphy P, Lakshmikuttyamma A. Effect of probiotics and gut microbiota on anti-cancer drugs: Mechanistic perspectives. Biochim Biophys Acta Rev Cancer 2021;1875:188494. [PMID: 33346129 DOI: 10.1016/j.bbcan.2020.188494] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
95 Ibraheim H, Green M, Papa S, Powell N. Topical beclometasone dipropionate in the management of immune checkpoint inhibitor-induced microscopic colitis. BMJ Case Rep 2019;12:e226481. [PMID: 30948391 DOI: 10.1136/bcr-2018-226481] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
96 Rajha E, Chaftari P, Kamal M, Maamari J, Chaftari C, Yeung SJ. Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy. Gastroenterol Rep (Oxf) 2020;8:25-30. [PMID: 32104583 DOI: 10.1093/gastro/goz065] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
97 Singh BP, Marshall JL, He AR. Workup and Management of Immune-Mediated Colitis in Patients Treated with Immune Checkpoint Inhibitors. Oncologist 2020;25:197-202. [PMID: 32162824 DOI: 10.1634/theoncologist.2018-0304] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
98 Fishman JA, Hogan JI, Maus MV. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies. Clin Infect Dis 2019;69:909-20. [PMID: 30520987 DOI: 10.1093/cid/ciy1025] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 30.0] [Reference Citation Analysis]
99 Wright AP, Piper MS, Bishu S, Stidham RW. Systematic review and case series: flexible sigmoidoscopy identifies most cases of checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther 2019;49:1474-83. [PMID: 31035308 DOI: 10.1111/apt.15263] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
100 Cho SY, Huff DT, Jeraj R, Albertini MR. FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls. Semin Nucl Med 2020;50:518-31. [PMID: 33059821 DOI: 10.1053/j.semnuclmed.2020.06.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
101 Isidro RA, Ruan AB, Gannarapu S, Raj D, Rahma O, Grover S, Srivastava A. Medication-specific variations in morphological patterns of injury in immune check-point inhibitor-associated colitis. Histopathology 2021;78:532-41. [PMID: 32931028 DOI: 10.1111/his.14248] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
102 Abu-Sbeih H, Wang Y. Management Considerations for Immune Checkpoint Inhibitor-Induced Enterocolitis Based on Management of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2020;26:662-668. [PMID: 31560045 DOI: 10.1093/ibd/izz212] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
103 Reddy HG, Schneider BJ, Tai AW. Immune Checkpoint Inhibitor-Associated Colitis and Hepatitis. Clin Transl Gastroenterol. 2018;9:180. [PMID: 30228268 DOI: 10.1038/s41424-018-0049-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 11.7] [Reference Citation Analysis]
104 Vindum HH, Agnholt JS, Nielsen AWM, Nielsen MB, Schmidt H. Severe steroid refractory gastritis induced by Nivolumab: A case report. World J Gastroenterol 2020; 26(16): 1971-1978 [PMID: 32390707 DOI: 10.3748/wjg.v26.i16.1971] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
105 Chan KK, Bass AR. Autoimmune complications of immunotherapy: pathophysiology and management. BMJ. [DOI: 10.1136/bmj.m736] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 25.0] [Reference Citation Analysis]
106 Smyrk TC. Practical Approach to the Flattened Duodenal Biopsy. Surgical Pathology Clinics 2017;10:823-39. [DOI: 10.1016/j.path.2017.07.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
107 Ibraheim H, Baillie S, Samaan MA, Abu-Sbeih H, Wang Y, Talley NJ, P Jones M, Powell N. Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis. Aliment Pharmacol Ther 2020;52:1432-52. [PMID: 32920854 DOI: 10.1111/apt.15998] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
108 Humphries A, Daud A. The gut microbiota and immune checkpoint inhibitors. Hum Vaccin Immunother 2018;14:2178-82. [PMID: 29494275 DOI: 10.1080/21645515.2018.1442970] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
109 Hines J, Daily E, Pham AK, Shea CR, Nadeem U, Husain AN, Stadler WM, Reid P. Steroid-refractory dermatologic and pulmonary toxicity in a patient on rituximab treated with pembrolizumab for progressive urothelial carcinoma: a case report. J Med Case Rep 2021;15:124. [PMID: 33736690 DOI: 10.1186/s13256-021-02670-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Halsey T, Ologun G, Wargo J, Jenq RR. Uncovering the role of the gut microbiota in immune checkpoint blockade therapy: A mini-review. Semin Hematol 2020;57:13-8. [PMID: 32690139 DOI: 10.1053/j.seminhematol.2020.05.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
111 Martín P, Blanco-Domínguez R, Sánchez-Díaz R. Novel human immunomodulatory T cell receptors and their double-edged potential in autoimmunity, cardiovascular disease and cancer. Cell Mol Immunol 2021;18:919-35. [PMID: 33235388 DOI: 10.1038/s41423-020-00586-4] [Reference Citation Analysis]
112 Bauché D, Mauze S, Kochel C, Grein J, Sawant A, Zybina Y, Blumenschein W, Yang P, Annamalai L, Yearley JH, Punnonen J, Bowman EP, Chackerian A, Laface D. Antitumor efficacy of combined CTLA4/PD-1 blockade without intestinal inflammation is achieved by elimination of FcγR interactions. J Immunother Cancer 2020;8:e001584. [PMID: 33127658 DOI: 10.1136/jitc-2020-001584] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
113 von Itzstein MS, Khan S, Gerber DE. Investigational Biomarkers for Checkpoint Inhibitor Immune-Related Adverse Event Prediction and Diagnosis. Clin Chem 2020;66:779-93. [PMID: 32363387 DOI: 10.1093/clinchem/hvaa081] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
114 Bamias G, Delladetsima I, Perdiki M, Siakavellas SI, Goukos D, Papatheodoridis GV, Daikos GL, Gogas H. Immunological Characteristics of Colitis Associated with Anti-CTLA-4 Antibody Therapy. Cancer Invest. 2017;35:443-455. [PMID: 28548891 DOI: 10.1080/07357907.2017.1324032] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
115 Hamdeh S, Micic D, Hanauer S. Drug-Induced Colitis. Clinical Gastroenterology and Hepatology 2021;19:1759-79. [DOI: 10.1016/j.cgh.2020.04.069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
116 Abu-Sbeih H, Wang Y. Gastrointestinal Tract Adverse Events. Adv Exp Med Biol 2020;1244:247-53. [PMID: 32301019 DOI: 10.1007/978-3-030-41008-7_12] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
117 Yanai S, Nakamura S, Matsumoto T. Nivolumab-Induced Colitis Treated by Infliximab. Clinical Gastroenterology and Hepatology 2017;15:e80-1. [DOI: 10.1016/j.cgh.2016.09.017] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 10.5] [Reference Citation Analysis]
118 Grover S, Rahma OE, Hashemi N, Lim RM. Gastrointestinal and Hepatic Toxicities of Checkpoint Inhibitors: Algorithms for Management. Am Soc Clin Oncol Educ Book 2018;38:13-9. [PMID: 30231401 DOI: 10.1200/EDBK_100013] [Cited by in Crossref: 32] [Cited by in F6Publishing: 9] [Article Influence: 10.7] [Reference Citation Analysis]
119 Badran YR, Shih A, Leet D, Mooradian MJ, Coromilas A, Chen J, Kem M, Zheng H, Borowsky J, Misdraji J, Mino-Kenudson M, Dougan M. Immune checkpoint inhibitor-associated celiac disease. J Immunother Cancer 2020;8:e000958. [PMID: 32581063 DOI: 10.1136/jitc-2020-000958] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
120 Papouin B, Mussini C, De Martin E, Guettier C. [Hepatic and digestive adverse events of immune checkpoint inhibitors (anti-CTLA-4 and, anti-PD-1/PD-L1): A clinico-pathological review]. Ann Pathol 2018;38:338-51. [PMID: 30143243 DOI: 10.1016/j.annpat.2018.07.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
121 Chen AY, Wolchok JD, Bass AR. TNF in the era of immune checkpoint inhibitors: friend or foe? Nat Rev Rheumatol 2021;17:213-23. [PMID: 33686279 DOI: 10.1038/s41584-021-00584-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
122 Badran YR, Cohen JV, Brastianos PK, Parikh AR, Hong TS, Dougan M. Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events. J Immunother Cancer 2019;7:226. [PMID: 31439050 DOI: 10.1186/s40425-019-0711-0] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 18.5] [Reference Citation Analysis]
123 Haanen JBAG, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K; ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv119-iv142. [PMID: 28881921 DOI: 10.1093/annonc/mdx225] [Cited by in Crossref: 853] [Cited by in F6Publishing: 736] [Article Influence: 284.3] [Reference Citation Analysis]
124 Muehler A, Slizgi JR, Kohlhof H, Groeppel M, Peelen E, Vitt D. Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases. World J Gastrointest Pathophysiol 2020; 11(6): 114-130 [PMID: 33362939 DOI: 10.4291/wjgp.v11.i6.114] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
125 Bozon A, Jeantet G, Rivière B, Funakoshi N, Dufour G, Combes R, Valats JC, Delmas S, Serre JE, Bismuth M, Ramos J, Le Quintrec M, Blanc P, Pineton de Chambrun G. Stricturing Crohn’s disease-like colitis in a patient treated with belatacept. World J Gastroenterol 2017; 23(48): 8660-8665 [PMID: 29358873 DOI: 10.3748/wjg.v23.i48.8660] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
126 Takenaka T, Yamazaki K, Miura N, Harada N, Takeo S. Osimertinib reactivated immune-related colitis after treatment with anti-PD1 antibody for non-small cell lung cancer. Invest New Drugs 2017;35:848-50. [PMID: 28601918 DOI: 10.1007/s10637-017-0481-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
127 Liu YH, Zang XY, Wang JC, Huang SS, Xu J, Zhang P. Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy. Biomed Pharmacother 2019;120:109437. [PMID: 31590992 DOI: 10.1016/j.biopha.2019.109437] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
128 Beck TN, Kudinov AE, Dulaimi E, Boumber Y. Case report: reinitiating pembrolizumab treatment after small bowel perforation. BMC Cancer 2019;19:379. [PMID: 31018834 DOI: 10.1186/s12885-019-5577-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
129 Carbonnel F, Soularue E, Coutzac C, Chaput N, Mateus C, Lepage P, Robert C. Inflammatory bowel disease and cancer response due to anti-CTLA-4: is it in the flora? Semin Immunopathol. 2017;39:327-331. [PMID: 28093620 DOI: 10.1007/s00281-016-0613-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 4.8] [Reference Citation Analysis]
130 Samaan MA, Pavlidis P, Papa S, Powell N, Irving PM. Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. Nat Rev Gastroenterol Hepatol. 2018;15:222-234. [PMID: 29512649 DOI: 10.1038/nrgastro.2018.14] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 14.0] [Reference Citation Analysis]
131 Connolly C, Bambhania K, Naidoo J. Immune-Related Adverse Events: A Case-Based Approach. Front Oncol 2019;9:530. [PMID: 31293970 DOI: 10.3389/fonc.2019.00530] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 9.0] [Reference Citation Analysis]
132 Tian Y, Abu-sbeih H, Wang Y. Immune Checkpoint Inhibitors-Induced Colitis. In: Naing A, Hajjar J, editors. Immunotherapy. Cham: Springer International Publishing; 2018. pp. 151-7. [DOI: 10.1007/978-3-030-02505-2_7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]